"たけだP" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonTakeda trims sales force to navigate patent loss - Новости GxP
Takeda trims sales force to navigate patent loss Новости GxP
Phase III wins in July include Apnimed, Livzon, Takeda - BioWorld MedTech
Phase III wins in July include Apnimed, Livzon, Takeda BioWorld MedTech
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? - Yahoo Finance
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? Yahoo Finance
Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech
Protagonist-Takeda, Novartis post phase III wins BioWorld MedTech
Earnings Tell The Story For Takeda Pharmaceutical Company Limited (TSE:4502) - simplywall.st
Earnings Tell The Story For Takeda Pharmaceutical Company Limited (TSE:4502) simplywall.st
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide ...
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? - Yahoo Finance
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? Yahoo Finance
Front Cover: Enantioselective α-Aminoxylation of Ketones Catalyzed by a Chiral Brønsted Acid (Adv...
Takeda’s TAK-861 Shows Promise in Improving Wakefulness in Phase 1 Trial Among Healthy Men - Neur...
Takeda’s TAK-861 Shows Promise in Improving Wakefulness in Phase 1 Trial Among Healthy Men NeurologyLive
Takeda PH promotes equitable access to medicines at SEA Summit - pna.gov.ph
Takeda PH promotes equitable access to medicines at SEA Summit pna.gov.ph
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on t...
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf Fierce Biotech
Iclusig comes too late to rescue Takeda | ApexOnco - Clinical Trials news and analysis - Oncology...
Iclusig comes too late to rescue Takeda | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Takeda’s Epilepsy Drug Stumbles in Back-to-Back Phase III Rare Disease Failures - BioSpace
Takeda’s Epilepsy Drug Stumbles in Back-to-Back Phase III Rare Disease Failures BioSpace
Korean pharmas race for generic P-CAB market amid Takeda's uncertain future for Vocinti - koreabi...
Korean pharmas race for generic P-CAB market amid Takeda's uncertain future for Vocinti koreabiomed.com
Tau Propagation as a Diagnostic and Therapeutic Target for Dementia: Potentials and Unanswered Qu...
Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK) - Seeking Alpha
Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK) Seeking Alpha
Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studie...
Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies NeurologyLive
Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data d...
Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data detail Fierce Biotech
Soticlestat Shows Mixed Results in Phase 3 Studies of Dravet and Lennox-Gastaut Syndrome - Neurol...
Soticlestat Shows Mixed Results in Phase 3 Studies of Dravet and Lennox-Gastaut Syndrome NeurologyLive
Scoop: San Diego Biotech Partners with Takeda, Lands $1.2B Milestone Deal - Substack
Scoop: San Diego Biotech Partners with Takeda, Lands $1.2B Milestone Deal Substack
Novel Drug Fails for Two Rare Seizure Disorders - MedPage Today
Novel Drug Fails for Two Rare Seizure Disorders MedPage Today
Epilepsy fail hands late-stage pipeline blow to Takeda - pharmaphorum
Epilepsy fail hands late-stage pipeline blow to Takeda pharmaphorum
A Look at Innovent Biologics (SEHK:1801) Valuation After Strategic Global Partnership With Takeda...
A Look at Innovent Biologics (SEHK:1801) Valuation After Strategic Global Partnership With Takeda Yahoo Finance
Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study - BioSpace
Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study BioSpace
ASCO: Takeda and Protagonist release positive Phase III VERIFY study of rusfertide in polycythemi...
ASCO: Takeda and Protagonist release positive Phase III VERIFY study of rusfertide in polycythemia vera The Pharma Letter
Takeda powers toward pivotal trials after phase 2b narcolepsy win but pauses multi-indication dre...
Takeda powers toward pivotal trials after phase 2b narcolepsy win but pauses multi-indication dream Fierce Biotech
Takeda taps Julie Kim as next CEO, 1st Korean American to lead global pharma company - koreabiome...
Takeda taps Julie Kim as next CEO, 1st Korean American to lead global pharma company koreabiomed.com
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris - The Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris The Motley Fool
Takeda’s market exit and return of vonoprazan raise stakes in Korea’s drug pricing battle - korea...
Takeda’s market exit and return of vonoprazan raise stakes in Korea’s drug pricing battle koreabiomed.com
Takeda Pushes One Narcolepsy Program into Phase III, Discontinues Another - BioSpace
Takeda Pushes One Narcolepsy Program into Phase III, Discontinues Another BioSpace
Takeda spinout Phathom's erosive esophagitis drug bests Prevacid in head-to-head phase 3 trial - ...
Takeda spinout Phathom's erosive esophagitis drug bests Prevacid in head-to-head phase 3 trial Fierce Biotech
Takeda Korea names Peter Trang as head of business operations - koreabiomed.com
Takeda Korea names Peter Trang as head of business operations koreabiomed.com
Clinical and molecular features of patients with COL1‐related disorders: Implications for the wid...
Takeda broadens gene therapy scope, turns to Poseida for non-viral approach - MedCity News
Takeda broadens gene therapy scope, turns to Poseida for non-viral approach MedCity News
‘Cooking is a beautiful thing’: A chef's journey from Hope to Estonia - Fraser Valley Current
‘Cooking is a beautiful thing’: A chef's journey from Hope to Estonia Fraser Valley Current
Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severe...
Host–microbiota interactions in rheumatoid arthritis - Nature
Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologi...
Organic Complementary Inverter Circuits Fabricated with Reverse Offset Printing - Wiley
Organic Complementary Inverter Circuits Fabricated with Reverse Offset Printing Wiley
Zydus inks licensing pact with Takeda to sell GERD drug - economictimes.com
Zydus inks licensing pact with Takeda to sell GERD drug economictimes.com
Paddington Life Sciences Symposium celebrates the power of collaboration in life sciences - Imper...
Paddington Life Sciences Symposium celebrates the power of collaboration in life sciences Imperial College Healthcare NHS Trust
Torrent Pharma, Takeda to commercialise GI drug in India - Times of India
Torrent Pharma, Takeda to commercialise GI drug in India Times of India
Torrent Pharma in pact with Takeda to commercialize acid reflux drug - Mint
Torrent Pharma in pact with Takeda to commercialize acid reflux drug Mint
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India - Indian Pharma Post
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India Indian Pharma Post
Takeda, Sanford-Burnham Launch Heart Failure Collaboration - GEN - Genetic Engineering and Biotec...
Takeda, Sanford-Burnham Launch Heart Failure Collaboration GEN - Genetic Engineering and Biotechnology News
Torrent pharma enters into non - exclusive patent licensing agreement with Takeda Pharma - Expres...
Torrent pharma enters into non - exclusive patent licensing agreement with Takeda Pharma Express Pharma
Zydus ties with Takeda to sell GERD drug - Mint
Tri-Institutional Therapeutics Discovery Institute, Inc. Launched by Memorial Sloan-Kettering Can...
Zydus announces licensing deal with Takeda for new GERD drug Vault - Business Standard
Zydus announces licensing deal with Takeda for new GERD drug Vault Business Standard
Mankind Pharma inks pact with Takeda to commercialise Vonoprazan in India - ET HealthWorld
Mankind Pharma inks pact with Takeda to commercialise Vonoprazan in India ET HealthWorld
Mankind Pharma in licensing pact with Takeda to market acidity drug Vonoprazan in India - economi...
Mankind Pharma in licensing pact with Takeda to market acidity drug Vonoprazan in India economictimes.com
Mankind Pharma inks pact with Takeda to commercialise acidity drug in India - Business Standard
Mankind Pharma inks pact with Takeda to commercialise acidity drug in India Business Standard
TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan - otsuka.co.jp
TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan otsuka.co.jp
Lupin joins hand with Takeda to Launch Vonoprazan Tablets in India - Business Standard
Lupin joins hand with Takeda to Launch Vonoprazan Tablets in India Business Standard
Mankind Pharma signs agreement with Takeda to commercialise novel drug for GERD treatment in Indi...
Mankind Pharma signs agreement with Takeda to commercialise novel drug for GERD treatment in India The Financial Express